The drugs that saved the man in the opening case never touched his cancer cells. They touched his T cells — specifically, they removed a molecular brake that his tumor had been pressing to keep his T cells from killing it. The tumor shrank because his own immune system, finally released, attacked it. This is the strange logic of cancer immunotherapy: treat the immune system, not the cancer.

In 2011, ipilimumab became the first drug ever to extend overall survival in metastatic melanoma. James Allison and Tasuku Honjo won the Nobel Prize in 2018 for the underlying science. Checkpoint blockade now has approvals across more than twenty cancer types, including a tumor-agnostic approval — the first in oncology — for any solid tumor with high microsatellite instability, regardless of where it started. This chapter explains how and why.

A T cell needs two signals to activate. The first is antigen — a peptide fragment from a foreign protein, binding the T-cell receptor. This provides specificity. The second is co-stimulation: the receptor C D 28 binding C D 80 or C D 86. This provides authorization. Without signal two, the T cell goes anergic — silenced. Immune checkpoints are inhibitory receptors that dampen T-cell activation. They are brakes, and they are necessary. The therapeutic insight is that tumors have learned to press these same brakes to shut down the T cells that would otherwise kill them.

The two checkpoints at the center of current therapy are not redundant — they operate at different steps. C T L A-4 appears on activated T cells and competes with C D 28 for the same binding sites, with higher affinity — effectively stealing signal two. Its dominant effect is at priming, in the lymph node, before any T cell has reached the tumor. P D-1 operates inside the tumor itself, at the killing step. Its ligand, P D-L 1, is upregulated by the very interferon-gamma that infiltrating T cells produce. The tumor's T cells announce their presence through interferon — and the tumor responds by upregulating the molecule that shuts them off. Block both checkpoints, and you attack the cancer-immunity cycle at two separate points.

Checkpoint blockade requires pre-existing anti-tumor T cells. When they do not exist, a different approach becomes relevant: CAR-T — chimeric antigen receptor T cells. A patient's T cells are collected by apheresis, engineered with a gene encoding an artificial receptor, expanded in culture, and reinfused. The chimeric antigen receptor combines an antibody-derived binding domain with intracellular T-cell signaling domains. Recognition is direct, without M H C presentation — meaning tumors that have downregulated M H C to hide from normal T cells are still vulnerable. In C D 19-positive B-cell acute lymphoblastic leukemia, tisagenlecleucel produced complete-response rates around 80 percent in heavily pretreated children who had no remaining options.

The success in B-cell malignancies reflects a confluence of favorable conditions that solid tumors do not share. C D 19 is on essentially all malignant B cells — no antigen-negative escape subclone. Losing normal B cells is survivable. And B-cell cancers are in the blood, physically accessible. Solid tumors violate each of these conditions. Antigen expression is heterogeneous across regions. Few solid-tumor antigens are truly cancer-specific rather than cancer-associated. And the solid-tumor microenvironment — dense extracellular matrix, hypoxia, nutrient depletion — physically impedes infiltration and exhausts the T cells that manage to get in. No CAR-T product for a solid tumor is yet approved, and this is not for lack of effort. The three obstacles are real and, at present, unsolved.

T I L therapy — expanding a patient's own tumor-infiltrating lymphocytes and reinfusing them — was approved in 2024 for melanoma. The cells are already tumor-reactive; the therapy provides numbers and reactivation. Personalized neoantigen vaccines sequence a patient's tumor, identify its unique mutant peptides, and manufacture a vaccine to prime T cells against those specific targets. A randomized trial of an m R N A neoantigen vaccine combined with pembrolizumab improved recurrence-free survival over pembrolizumab alone in melanoma. The pairing is mechanistically natural: the vaccine generates new anti-tumor T-cell responses, and the checkpoint inhibitor prevents the tumor from shutting those responses down. One component addresses the cold-tumor problem — insufficient T cells. The other addresses suppression. Together they cover both steps.

Here is the chapter's central claim. Checkpoint blockade works by releasing brakes on pre-existing, primed anti-tumor T cells — which is why infiltrated, high-mutation tumors respond and T-cell-poor, low-mutation tumors do not. The finding that would force revision: durable responses at meaningful rates in tumors verified before treatment to have no neoantigen-specific T cells anywhere in the patient. The correlational evidence makes this unlikely — but a clean contradicting result would break the framework. What we still cannot explain: why some patients sustain remission for a decade after stopping therapy while others with apparently identical tumors relapse. And whether immune toxicity and anti-tumor response can ever be mechanistically uncoupled.